Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality and
Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality and
Global clinical trials are a vital part of the drug development process. But when it comes to clinical trial patient recruitment, a standardized global approach fails to consider factors such as differing cultures, healthcare systems and patient needs. Instead, success hinges on local strategies for clinical trial patient recruitment. In a recent webinar,
Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality and
Global clinical trials are a vital part of the drug development process. But when it comes to clinical trial patient recruitment, a standardized global approach fails to consider factors such as differing cultures, healthcare systems and patient needs. Instead, success hinges on local strategies for clinical trial patient recruitment. In a recent webinar,
Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality and
This November, we are celebrating the US holiday of Thanksgiving. As we join our American colleagues in marking the occasion, Kate Shaw, our Founder, and Chief Executive Officer, looks back on one achievement she is most thankful for - our first international office in the US - and shares how this is already
As we move deeper into the realm of personalized treatments, effective communication and relationships between the pharmaceutical industry, healthcare professionals and patients has never been more important. This is particularly true for rare disease trials. The global rare disease market is set to be worth more than 547 billion US dollars by 2030. However,
More than two years since COVID-19 began spreading across the world, we continue to feel its impact. Clinical trials, which were suspended during the pandemic and have since restarted, have created a research backlog. Sponsors and sites are subsequently struggling to cope with such high enrollment demands. In a recent webinar, our Founder and
Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical research. Whether it is wanting to see more people from underrepresented communities choosing science as a career and pushing for greater patient diversity in clinical trials or focusing on what we are doing internally to celebrate and promote equality